BioNTech Gestione

Gestione criteri di controllo 4/4

BioNTech Il CEO è Ugur Sahin, nominato in Jan2008, e ha un mandato di 16.83 anni. la retribuzione annua totale è € 3.06M, composta da 22.9% di stipendio e 77.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 17.23% delle azioni della società, per un valore di € 4.02B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 4.6 anni.

Informazioni chiave

Ugur Sahin

Amministratore delegato

€3.1m

Compenso totale

Percentuale dello stipendio del CEO	22.9%
Mandato del CEO	16.8yrs
Proprietà del CEO	17.2%
Durata media del management	3.3yrs
Durata media del Consiglio di amministrazione	4.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ugur Sahin rispetto agli utili di BioNTech?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-€467m
Jun 30 2024	n/a	n/a	-€504m
Mar 31 2024	n/a	n/a	€113m
Dec 31 2023	€3m	€700k	€930m
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€4b
Mar 31 2023	n/a	n/a	€6b
Dec 31 2022	€6m	€360k	€9b
Sep 30 2022	n/a	n/a	€10b
Jun 30 2022	n/a	n/a	€12b
Mar 31 2022	n/a	n/a	€13b
Dec 31 2021	€12m	€360k	€10b
Sep 30 2021	n/a	n/a	€7b
Jun 30 2021	n/a	n/a	€4b
Mar 31 2021	n/a	n/a	€1b
Dec 31 2020	€17m	€360k	€15m
Sep 30 2020	n/a	n/a	-€410m
Jun 30 2020	n/a	n/a	-€230m
Mar 31 2020	n/a	n/a	-€192m
Dec 31 2019	€7m	€311k	-€179m
Sep 30 2019	n/a	n/a	-€122m
Jun 30 2019	n/a	n/a	-€116m
Mar 31 2019	n/a	n/a	-€77m
Dec 31 2018	€653k	€210k	-€48m

Compensazione vs Mercato: La retribuzione totale di Ugur ($USD 3.20M ) è circa la media per le aziende di dimensioni simili nel mercato Austrian ($USD 4.40M ).

Compensazione vs guadagni: La retribuzione di Ugur è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Ugur Sahin (59 yo)

16.8yrs

Mandato

€3,056,000

Compensazione

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ugur Sahin	Co-Founder	16.8yrs	€3.06m	17.23% € 4.0b
Ozlem Tureci	Co-Founder	6.8yrs	€814.00k	0.38% € 89.0m
Jens Holstein	CFO & Member of Management Board	3.3yrs	€1.32m	0.00068% € 158.9k
Sierk Poetting	MD, COO & Member of Management Board	10.8yrs	€821.00k	0.31% € 73.5m
Ryan Richardson	Chief Strategy Officer	4.8yrs	€1.41m	0.0061% € 1.4m
James Timothy Ryan	Chief Legal & Business Officer & Member of the Management Board	1.2yrs	€848.00k	Nessun dato
Sean Marett	Executive Officer	less than a year	€133.00k	0.34% € 79.4m
Lisa Birringer	Senior Vice President of Global Financial Reporting & Accounting	less than a year	Nessun dato	Nessun dato
Zach Taylor	Senior Vice President of Corporate Development & Strategy	less than a year	Nessun dato	Nessun dato
Katalin Kariko	Senior VP & External Consultant for RNA Protein Replacement Therapies	no data	Nessun dato	Nessun dato
Oliver Henning	Senior Vice President of Operations	no data	Nessun dato	Nessun dato
Sebastian Kreiter	Senior Vice President of Immunotherapy & Preclinical Research	no data	Nessun dato	Nessun dato

3.3yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di BNTX è considerato esperto (durata media dell'incarico 3.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Rudolf Staudigl	Supervisory Board Member	2.4yrs	€90.00k	0.00017% € 39.7k
Ulrich Wandschneider	Independent Deputy Chairman Supervisory Board	6.8yrs	€114.00k	Nessun dato
Michael Motschmann	Independent Supervisory Board Member	16.8yrs	€80.00k	Nessun dato
Helmut Jeggle	Independent Supervisory Board Chairman	16.8yrs	€226.00k	0.14% € 32.4m
Nicola Blackwood	Member of Supervisory Board	1.5yrs	€46.00k	Nessun dato
Anja Morawietz	Supervisory Board Member	2.4yrs	€105.00k	0.00010% € 23.4k

4.6yrs

Durata media

58.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BNTX sono considerati esperti (durata media dell'incarico 4.6 anni).

BioNTech Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

Recent updates

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: €0.82 (vs €0.67 in 3Q 2023)

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

New major risk - Revenue and earnings growth

New major risk - Share price stability

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH

Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023)

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: €1.31 loss per share (vs €2.07 profit in 1Q 2023)

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

New major risk - Revenue and earnings growth

New minor risk - Profit margin trend

Full year 2023 earnings released: EPS: €3.87 (vs €38.78 in FY 2022)

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

New minor risk - Shareholder dilution

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

Third quarter 2023 earnings released: EPS: €0.67 (vs €7.43 in 3Q 2022)

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

BioNTech SE, Annual General Meeting, May 17, 2024

Investor sentiment deteriorates as stock falls 16%

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

Second quarter 2023 earnings released: €0.79 loss per share (vs €6.86 profit in 2Q 2022)

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.

BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023

BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

New minor risk - Share price stability

BioNTech SE Provides Revenue Guidance for the Full Year 2023

Full year 2022 earnings released: EPS: €38.78 (vs €42.18 in FY 2021)

BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

Third quarter 2022 earnings released: EPS: €7.43 (vs €13.14 in 3Q 2021)

BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Pfizer and Biontech Receive Positive CHMP Opinion for Comirnaty® in Children 6 Months to Less Than 5 Years in the European Union

Pfizer and BioNTech Announce Positive Early Data from Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Canada ULC and BioNTech SE's Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Inc. and BioNTech SE Receive Positive Chmp Opinion for Conversion of Comirnaty® Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster in European Union

Biontech Presents Encouraging Phase 1/2 Follow-Up Data for Car-T Candidate Bnt211 in Hard-To-Treat Solid Tumors At ESMO

Pfizer Inc. and BioNTech SE Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older